Ampio Pharmaceuticals

Ampio Pharmaceuticals closes enrollment in the OptimEyes study

Friday, June 27, 2014

Ampio Pharmaceuticals has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes study for the treatment of diabetic macular edema (oral treatment with Optina). This trial was intended to enroll 450 patients and was powered at 95%. The present enrollment of over 355 patients provides an adequate power of 88%, which the company believes is more than sufficient for statistical evaluation.

[Read More]

Ampio Pharmaceuticals appoints Gregory A. Gould CFO

Friday, June 6, 2014

Ampio Pharmaceuticals has appointed Gregory A. Gould chief financial officer, treasurer and corporate secretary. Gould, a veteran of the pharmaceutical and life sciences industry, is joining the company effective June 10. Mark McGregor, the company’s current chief financial officer, will retire from Ampio Pharmaceuticals following a transition period later this year.

[Read More]

Ampio Pharmaceuticals’ Vyrix inks agreement with Paladin Labs

Monday, April 14, 2014

Ampio Pharmaceuticals’ wholly-owned subsidiary Vyrix Pharmaceuticals, a specialty pharma company focused on developing and commercializing late-stage prescription pharmaceuticals to improve men’s sexual health, has signed an agreement with Paladin Labs, a Canadian specialty pharma company, to provide exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, Sub-Saharan Africa and Latin America.

[Read More]

Luoxis enters collaborations on oxidative stress

Monday, January 6, 2014

Ampio Pharmaceuticals has announced that its subsidiary, biotechnology company Luoxis, has entered into research agreements with Western Galilee Medical Center and the University of Thessaly. These two oxidative stress research groups will utilize Luoxis’ proprietary RedoxSYS oxidation-reduction potential (ORP) diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis and physical exertion.

[Read More]

Ampio Pharmaceuticals announces positive results from Optina trial

Tuesday, October 8, 2013

Ampio Pharmaceuticals, a development stage biopharmaceutical company, has announced interim results from the ongoing 450 patient, dose finding, 505(b)(2) study of Optina as a treatment for Diabetic Macular Edema (DME). This interim analysis was conducted by an Independent Data Review Committee (IDRC) comprised of a statistician and an ophthalmologist/retinologist, who were permitted to view the unmasked data from the trial. At least 30% of patients had reached the first four-week time point and their clinical results were considered representative data for the trial.

[Read More]